ABBV vs PLTR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Palantir Technologies Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Palantir Technologies Inc. · Technology
$128.47
-41.4% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
ABBV trades at a lower forward P/E
(128.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PLTR |
| Current Price |
$261.07 |
$128.47 |
| Fair Value Estimate |
$264.30 |
$75.23 |
| Upside to Fair Value |
+1.2%
|
-41.4%
|
| Market Cap |
$461.3B |
$295.0B |
| Forward P/E |
128.0x
|
133.8x
|
| EV / EBITDA |
31.0x
|
124.7x
|
| Price / Sales |
7.3x
|
56.5x
|
| Price / FCF |
22.1x
|
109.7x
|
| Revenue Growth YoY |
+12.4%
|
+84.7%
|
| Gross Margin |
70.7%
|
84.1%
|
| Operating Margin |
27.6%
|
38.1%
|
| Return on Equity |
68.0%
|
32.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
0.91%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Palantir Technologies Inc. is a software infrastructure company specializing in data analytics platforms primarily serving government and commercial clients. The company benefits from a durable competitive moat in government and select commercial verticals, driven by long-tenured founder leadership and high insider ownership. Palantir exhibits very strong recent growth with revenue up approximate…
Accumulation Zones
| Metric |
ABBV |
PLTR |
| Zone Low |
$198.23 |
$56.42 |
| Zone High |
$224.66 |
$63.95 |
| In Buy Zone? |
No
|
No
|